Glenmark Specialty has entered into an exclusive licence, collaboration and distribution agreement with Jiangsu Hansoh Pharmaceutical Group for aumolertinib, a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

Under the terms of the agreement, Glenmark receives exclusive rights to develop and commercialise Aumolertinib across its licensed territories: Middle East and Africa, Southeast and South Asia, Australia, New Zealand, Russia/CIS and a few selected Caribbean countries covered by the agreement.

Hansoh Pharma will receive an upfront payment of low double-digit million USD, followed by potential regulatory and commercial milestone payments possibly cumulating to over USD 1 billion, in addition to tiered royalties on net sales in the licensed territories.

“At Glenmark, we remain focused on building a growth-oriented oncology business across high-potential markets. Aumolertinib is a strategic addition that strengthens our near-term commercial pipeline and enhances our ability to serve patients with EGFR-mutated lung cancer. This collaboration reinforces our disciplined approach to expanding our innovative portfolio and widening access to advanced cancer care across key markets,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.

Aumolertinib, as a monotherapy, has received marketing authorisation from the UK MHRA and is indicated the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating Epidermal Growth Factor Receptor (EGFR) mutations, and the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. It has also received approval for four indications in China (second-line T790M mutation, first-line NSCLC EGFR mutated, unresectable Stage III post-chemoradiotherapy and adjuvant Stage II–IIIB NSCLC). Aumolertinib became Hansoh Pharma’s first innovative drug approved in an overseas market and the first China-developed EGFR-TKI to be launched internationally.